← FDA DRUG APPROVALS

FDA ANDA · ANDA208859

DOCETAXEL

docetaxel anhydrous

Sponsor: MYLAN LABS LTD

APPLICATION
ANDA208859
TYPE
ANDA
ORIGINAL APPROVAL
2018-04-30
LATEST ACTION
2024-02-23
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

DOCETAXELPrescription
DOCETAXEL 160MG/16ML (10MG/ML) · INJECTABLE · INJECTION

Approval history

2024-02-23Labeling · Supplement 9 · standardAP
2024-02-23Labeling · Supplement 7 · standardAP
2020-09-23Labeling · Supplement 4 · standardAP
2019-09-05Labeling · Supplement 2 · standardAP
2018-04-30UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →